Đang chuẩn bị liên kết để tải về tài liệu:
The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Neo-adjuvant breast cancer clinical trials of zoledronic acid (ZOL) have shown that patients with oestrogen negative (ER-ve) tumours have improved disease outcomes. We investigated the molecular mechanism behind this differential anti-tumour effect according to ER status, hypothesising it may in part be mediated via the activin signaling pathway. |